← Back to Analyst Consensus 
XFOR Buy
X4 Pharmaceuticals, Inc
Current Price —
Implied Upside —
Analysts 11
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 3, 2026 (8 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Jul 10, 2026 | Wells Fargo | initiate | — → Overweight | — | 54% |
| Jun 2, 2026 | Leerink Partners | initiate | — → Outperform | — | 51% |
| Mar 9, 2026 | Guggenheim | initiate | — → Buy | — | 52% |
| Dec 5, 2025 | Stifel | maintain | Buy → Buy | $10 | 53% |
| Nov 10, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $5 | 44% |
| Aug 29, 2025 | Stifel | maintain | Buy → Buy | $9 | 53% |
| Aug 13, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $3.5 | 44% |
| May 2, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $7 | 44% |
| Mar 27, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $1.5 | 44% |
| Mar 26, 2025 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $3 | 50% |
| Feb 7, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $1.5 | 44% |
| Jan 14, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $1.5 | 44% |
| Nov 14, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $1.5 | 44% |
| Nov 14, 2024 | Stifel | maintain | Buy → Buy | $4 | 53% |
| Jun 28, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $5 | 44% |
| May 31, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $5 | 50% |
| Apr 30, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $5 | 44% |
| Mar 22, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $3 | 44% |
| Dec 12, 2023 | B. Riley Securities | downgrade | Buy → Neutral | $1 | 55% |
| Aug 11, 2023 | HC Wainwright & Co. | reiterate | Buy → Buy | $3 | 44% |
| May 17, 2023 | Stifel | maintain | Buy → Buy | $5 | 53% |
| May 5, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $3 | 44% |
| Apr 10, 2023 | B. Riley Securities | maintain | — → Buy | $3 | 55% |
| Mar 24, 2023 | Oppenheimer | maintain | — → Outperform | $4 | 52% |
| Mar 22, 2023 | Cantor Fitzgerald | maintain | — → Overweight | $3 | 50% |
| Mar 22, 2023 | HC Wainwright & Co. | maintain | — → Buy | $3 | 44% |
| Dec 22, 2022 | Cantor Fitzgerald | initiate | — → Overweight | $3 | 50% |
| Dec 12, 2022 | Piper Sandler | initiate | — → Overweight | $3 | 54% |
| Nov 30, 2022 | HC Wainwright & Co. | maintain | — → Buy | $5 | 44% |
| May 19, 2022 | B. Riley Securities | maintain | — → Buy | $7 | 55% |
| May 13, 2022 | HC Wainwright & Co. | maintain | — → Buy | $8.5 | 44% |
| Apr 5, 2022 | Canaccord Genuity | maintain | — → Buy | $10 | 48% |
| Dec 14, 2021 | HC Wainwright & Co. | maintain | — → Buy | $11 | 44% |
| Dec 17, 2020 | Brookline Capital | initiate | — → Buy | $21 | 38% |
| Nov 9, 2020 | Canaccord Genuity | maintain | — → Buy | $20 | 48% |
| May 8, 2020 | HC Wainwright & Co. | reiterate | — → Outperform | $21 | 44% |
| May 8, 2020 | B. Riley Securities | maintain | — → Buy | $15 | 55% |
| Mar 26, 2020 | Citigroup | maintain | — → Buy | $15 | 54% |
| Mar 13, 2020 | B. Riley Securities | maintain | — → Buy | $19 | 55% |
| Jan 7, 2020 | HC Wainwright & Co. | initiate | — → Buy | $22 | 44% |
| Dec 23, 2019 | Oppenheimer | initiate | — → Outperform | $20 | 52% |
| Dec 18, 2019 | Roth Capital | initiate | — → Buy | $20 | 53% |
| Dec 9, 2019 | Citigroup | upgrade | Neutral → Buy | $0 | 54% |
| Dec 5, 2019 | B. Riley Securities | initiate | — → Buy | $25 | 55% |
| Jun 7, 2019 | Stifel | initiate | — → Buy | $27 | 53% |
| May 21, 2019 | Canaccord Genuity | initiate | — → Buy | $27 | 48% |
Price Target Trend
Apr 21, 2026 Latest: $11.6 Oct 25, 2026
EPS Estimates
0y $-0.67
Lo: $-0.79 Hi: $-0.59
5 analysts ▲2
0q $-0.19
Lo: $-0.22 Hi: $-0.16
5 analysts ▲1
+1y $-0.77
Lo: $-1.00 Hi: $-0.65
4 analysts +1q $-0.20
Lo: $-0.28 Hi: $-0.16
5 analysts ▲1
Cross-Platform Signals
No cross-platform signals in the last 90 days